HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Clinical trial NCT01683188 · TERMINATED
Trial details
- NCT number
- NCT01683188
- Sponsor
- Clinigen, Inc.
- Status
- TERMINATED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2012-08-01
- Primary completion
- 2014-11-01
- Enrollment
- 53
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.